SG Americas Securities LLC Has $831,000 Holdings in CRISPR Therapeutics AG (NASDAQ:CRSP)

SG Americas Securities LLC decreased its holdings in CRISPR Therapeutics AG (NASDAQ:CRSPFree Report) by 17.9% during the 4th quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The fund owned 21,101 shares of the company’s stock after selling 4,610 shares during the quarter. SG Americas Securities LLC’s holdings in CRISPR Therapeutics were worth $831,000 at the end of the most recent reporting period.

Several other institutional investors also recently modified their holdings of CRSP. MCF Advisors LLC bought a new stake in CRISPR Therapeutics during the fourth quarter valued at $80,000. Arkadios Wealth Advisors raised its holdings in shares of CRISPR Therapeutics by 7.7% in the 4th quarter. Arkadios Wealth Advisors now owns 12,161 shares of the company’s stock worth $479,000 after acquiring an additional 866 shares during the last quarter. Mirador Capital Partners LP acquired a new stake in shares of CRISPR Therapeutics in the 4th quarter worth about $297,000. Hennion & Walsh Asset Management Inc. raised its holdings in shares of CRISPR Therapeutics by 9.2% in the 4th quarter. Hennion & Walsh Asset Management Inc. now owns 44,305 shares of the company’s stock worth $1,744,000 after acquiring an additional 3,737 shares during the last quarter. Finally, 180 Wealth Advisors LLC increased its stake in CRISPR Therapeutics by 18.4% in the 4th quarter. 180 Wealth Advisors LLC now owns 5,167 shares of the company’s stock valued at $203,000 after buying an additional 803 shares during the last quarter. Institutional investors own 69.20% of the company’s stock.

Insider Buying and Selling

In other news, CEO Samarth Kulkarni sold 30,000 shares of CRISPR Therapeutics stock in a transaction that occurred on Monday, November 11th. The shares were sold at an average price of $55.62, for a total transaction of $1,668,600.00. Following the sale, the chief executive officer now owns 196,540 shares of the company’s stock, valued at approximately $10,931,554.80. The trade was a 13.24 % decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link. 4.10% of the stock is currently owned by insiders.

Wall Street Analyst Weigh In

A number of equities research analysts recently commented on the stock. Bank of America lowered their price target on shares of CRISPR Therapeutics from $98.00 to $85.00 and set a “buy” rating on the stock in a report on Tuesday, January 7th. Chardan Capital reiterated a “buy” rating and set a $94.00 target price on shares of CRISPR Therapeutics in a research report on Tuesday, December 10th. Royal Bank of Canada reissued a “sector perform” rating and issued a $53.00 price target on shares of CRISPR Therapeutics in a research report on Wednesday, November 6th. StockNews.com upgraded shares of CRISPR Therapeutics to a “sell” rating in a research report on Monday, December 30th. Finally, Barclays cut their price objective on CRISPR Therapeutics from $59.00 to $55.00 and set an “equal weight” rating for the company in a report on Wednesday, November 6th. Two equities research analysts have rated the stock with a sell rating, eight have assigned a hold rating and ten have issued a buy rating to the stock. According to data from MarketBeat, the company has an average rating of “Hold” and an average target price of $78.38.

Check Out Our Latest Research Report on CRISPR Therapeutics

CRISPR Therapeutics Price Performance

Shares of CRSP stock opened at $41.21 on Thursday. The firm has a market capitalization of $3.52 billion, a price-to-earnings ratio of -14.56 and a beta of 1.68. The business has a fifty day moving average of $43.97 and a 200 day moving average of $47.42. CRISPR Therapeutics AG has a 1 year low of $36.52 and a 1 year high of $91.10.

CRISPR Therapeutics (NASDAQ:CRSPGet Free Report) last released its quarterly earnings data on Tuesday, November 5th. The company reported ($1.01) earnings per share for the quarter, beating analysts’ consensus estimates of ($1.42) by $0.41. CRISPR Therapeutics had a negative return on equity of 12.15% and a negative net margin of 118.13%. The business had revenue of $0.60 million during the quarter, compared to analyst estimates of $6.65 million. During the same quarter last year, the business posted ($1.41) EPS. As a group, equities research analysts expect that CRISPR Therapeutics AG will post -5.13 earnings per share for the current year.

CRISPR Therapeutics Profile

(Free Report)

CRISPR Therapeutics is a gene-editing company focused on developing transformative gene-based medicines for serious diseases using its proprietary CRISPR/Cas9 platform. CRISPR/Cas9 is a revolutionary gene-editing technology that allows for precise, directed changes to genomic DNA. CRISPR Therapeutics has established a portfolio of therapeutic programs across a broad range of disease areas including hemoglobinopathies, oncology, regenerative medicine and rare diseases.

Featured Articles

Want to see what other hedge funds are holding CRSP? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for CRISPR Therapeutics AG (NASDAQ:CRSPFree Report).

Institutional Ownership by Quarter for CRISPR Therapeutics (NASDAQ:CRSP)

Receive News & Ratings for CRISPR Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for CRISPR Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.